CLINUVEL PHARMACEUTICALS earnings per share and revenue

UR9 earnings per share for the last semiannual are 0.13 EUR whereas the estimation was 0.16 EUR which accounts for -17.65% surprise. Company revenue for the same period amounts to 19.90 M EUR despite the estimated figure of 21.46 M EUR. Estimated earnings per share for the next semiannual are 0.28 EUR, and revenue is expected to reach 35.05 M EUR. Also watch annual changes over time to get a bigger picture of UR9 earnings per share and revenue dynamics.